Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 14 2026

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 4 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced that its drug Desidustat has received approval from the National Medical Products Administration of China for treating renal anaemia. This approval follows positive results from a Phase III clinical trial conducted in China. The Managing Director of Zydus expressed confidence that this partnership will enhance access to treatment for patients in Greater China.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 14, 2026, titled "Zydus new drug discovery, Desidustat licensed to China Medical System Holdings receives approval from NMPA of China".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases